Skip to contentB
Biofrontera Inc.
B
BFRIBiofrontera Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$12.56M$12.56Mderived+18.5% vs Q4 2023 Net Income-$1.40M-$1.40MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biofrontera Inc. · CIK 1858685 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$1,712,000N/M Operating Cash Flowderived-$1,017,000N/M Free Cash Flowderived-$1,018,000N/M Margins · derivedOperating margin-13.6%+22.9 pt vs Q4 2023
Net margin-11.1%−44.4 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 20, 2025 · 79 d after period end